Investigating the Relationship Between Blood Pressure and Serum FGF23 Level in Patients Undergoing Hemodialysis in Guilan Province, A Cross Sectional Study

The aim of current study is investigation of the impact of serum FGF23 levels on blood pressure of patients with end-stage renal disease (ESRD) undergoing hemodialysis. Methods. Based on registry, 68 patients who underwent hemodialysis (HD) in the dialysis center of Shahid Beheshti hospital, Anzali, north of Iran, from April 2016 to May 2017 were enrolled. Enzyme- Linked ImmunoSorbent Assay (ELISA) was used to determine serum FGF23 levels. 24 hours blood pressure monitoring method, AMBB, was used to monitor the mean arterial pressure of patients. Spearman related analysis method was used to statistically analyze the correlation of serum FGF23 level with mean arterial pressure, age, HD duration, kt/v, URR weight gaining, cause of ESRD, and the mentioned laboratory parameters. Results. Serum FGF23 levels of ESRD patients were not significantly related to age, time of HD and gaining weight. Furthermore, these parameters were not related to blood pressure. However, FGF23 expression levels in serum were positively correlated with phosphorous and calcium- phosphorous. The mentioned laboratory parameters had no significant correlation with 24 hours blood pressure changes. Meanwhile, the minimum diastolic pressure and intact parathyroid hormone (iPTH) level showed a significant direct linear correlation. Conclusion. We suggest that understanding relationship between phosphate, FGF23 and cardiovascular disease can be applied in targeted phosphate-based treatment. Kidney failure and the nondipper condition may be highly related to one another and lead to ESRD. Therefore, a special investment in controlling blood pressure and examining it with a tool such as ABPM can greatly help patients to progress effectively.